About Pardes Biosciences
Pardes Biosciences is a Healthcare company based in Berkeley (United States) founded in 2020, and was acquired by Foresite Capital in July 2023. Therapeutics for pandemic diseases including SARS-CoV-2 are developed. Pardes Biosciences has raised $51.61 million across 1 funding round from investors including Foresite Capital. The company has 29 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is PARDES BIOSCIENCES, INC. Its competitors include Vaxxinity, NRx and Inimmune; 2 of its 3 listed competitors have raised funding.
Company details
Pardes Biosciences was founded in 2020 and is based in Berkeley, United States. Focus is placed on the biotechnology sector, where therapeutics for pandemic diseases are developed. Operations center on antiviral drug candidates, with the lead product PBI-0451 serving as an oral coronaviral protease inhibitor. This compound is targeted at treating and preventing SARS-CoV-2 infections in clinical settings.
- Headquarters Berkeley, United States
- Employees 29
- Stage Acquired
- SectorsHealthcare
- Website pardesbio.com
- Social LinkedIn
- Acquired by Foresite Capital (Jul 2023)
- Legal Name Pardes Biosciences, Inc.
- Total Equity Funding$51.61M (USD)
in 1 rounds
- Latest Funding Round$51.61M (USD), Series C
Feb 2021
- Investors
- Employee Count29
- Acquired byForesite Capital
(Jul 2023)
Funding Insights of Pardes Biosciences
Pardes Biosciences has successfully raised a total of $51.61M through 1 strategic funding round. The most recent funding activity was a Series C round of $51.61 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.61M
- Total Rounds 1
- Last Round Series C — $51.61M
- First Round $51.61M
(Feb 2021)
All 1 funding rounds of Pardes Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $51.61M | Series C | – | – | – |
1 investors in total: 1 institutional.
Investors in Pardes Biosciences
Pardes Biosciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States |
Investor details for Pardes Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pardes Biosciences
30 people are tracked at Pardes Biosciences (12 in leadership, 15 in board & advisors, 3 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Jeanne Gange | Associate Director, Human Resources | Leadership |
Tom Wiggans | CEO & Chair | Leadership |
Sean Brusky | Chief Commercial Officer | Leadership |
Heidi Henson | Chief Financial Officer | Leadership |
Steve Henck | Vice President, Market Access & Channel Innovations | Leadership |
Jackie Tran | VP, Finance | Leadership |
Sally-Anne T. | Director, SEC Reporting And Technical Accounting (winding Down) | Leadership |
Sandra Umphreyville | Director, Finance | Leadership |
Jenna Tagliaferri | Vice President, Head Of Quality | Leadership |
Darryl Byrne | Director of Information Technology | Leadership |
Kathleen Villamejor | Executive Director, Clinical Operations | Leadership |
Mandy ·P | Chief Operating Officer，member Of Corporate Strategy Advisory Board | Leadership |
Mark Auerbach | Board Chair | Board & advisors |
Jay Lobell | Board Member | Board & advisors |
Mike Varney | Board Member & Scientific Advisory Board | Board & advisors |
Carol Brosgart | Scientific Advisory Board | Board & advisors |
Brad Jenkins | Commercial Advisory Board | Board & advisors |
Philippe Tinmouth | Commercial Advisory Board | Board & advisors |
James B. Tananbaum | Board Member | Board & advisors |
Clifford Samuel | Commercial Advisory Board | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for Pardes Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pardes Biosciences
3 dated milestones of Pardes Biosciences across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Pardes Biosciences is founded.
- Funding First funding round of $51.6M.
- Exit Acquired by Foresite Capital.
Competitors of Pardes Biosciences
Pardes Biosciences has 3 listed competitors in our database, 2 of them funded. They include Vaxxinity, NRx and Inimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vaxxinity.com | 2019 | Dallas, United States | $26.96M | 92 | Vaccines for neurological disorders and infectious diseases are developed. | |
| nrxpharma.com | 2017 | Wilmington, United States | Therapeutics for COVID-19 and neurological disorders are developed. | |||
| inimmune.com | 2016 | Missoula, United States | $22M | 35 | Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders |
Detailed competitors of Pardes Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Pardes Biosciences (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pardes Biosciences
Complete news archive for Pardes Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pardes Biosciences
Pardes Biosciences was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Pardes Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Pardes Biosciences is a funded company, having raised a total of $51.61M across 1 funding round to date. The company's 1st funding round was a Series C of $51.61M, raised on Feb 2021.
Pardes Biosciences has 29 employees.
Pardes Biosciences was founded in 2020 and is based in Berkeley, United States. Focus is placed on the biotechnology sector, where therapeutics for pandemic diseases are developed. Operations center on antiviral drug candidates, with the lead product PBI-0451 serving as an oral coronaviral protease inhibitor. This compound is targeted at treating and preventing SARS-CoV-2 infections in clinical settings.
Pardes Biosciences has 1 investor. Key investors include Foresite Capital.
Pardes Biosciences operates through Pardes Biosciences, Inc..
Yes. Pardes Biosciences was acquired by Foresite Capital in July 2023.